FDA delays decision on Bristol Myers-2seventy bio cancer therapy, stock falls

Bristol Myers Squibb and 2seventy bio announced that the U.S. FDA will not meet the December 16 deadline for potential approval of their blood cancer therapy, Abecma, for earlier lines of treatment. As a result, shares of Bristol Myers Squibb and 2seventy bio fell premarket.

Articles published about this story
More stories